Swiss biotech Molecular Partners, backed by several venture capital firms, is set to raise CHF 96m in its IPO on the Swiss Exchange, having resumed flotation plans after delaying the listing last month.
Sponsor remains on the road for its eighth flagship fund amid turmoil at CEO-level, with fundraising lagging behind peers KKR and EQT
Sponsor has held a EUR 150m first close for its latest fund and will back Central European businesses with flexible capital
Lazard to advise on auction for Dutch cloud-based contact centre and dialogue-management platform
AEA and management have reinvested for a minority stake in the Danish logistics provider